Corona Remedies IPO open date is December 8, 2025 and the IPO will close on December 10, 2025. Corona Remedies IPO is a Book Built Issue. The company to raise around ₹655.37 crores via IPO that comprises fresh issue of ₹[.] crores and offer for sale up to 61,71,101 equity shares with face value of ₹10 each.
Corona Remedies IPO price band is ₹1008 to ₹1062 per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Corona Remedies IPO to list on BSE, NSE on December 15, 2025. The allotment of Corona Remedies IPO date is December 11, 2025.
The company reported revenue of ₹1,202.35 crores in 2025 against ₹1,020.93 crores in 2024. As per the financials the IPO investors should apply the IPO for a long term.
Corona Remedies IPO Details
| IPO Open Date | December 8, 2025 |
| IPO Close Date | December 10, 2025 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹1008 to ₹1062 Per Share |
| Issue Size | Approx ₹655.37 Crores |
| Offer for Sale: | Approx 61,71,101 Equity Shares |
| Issue Type | Book Built Issue |
| IPO Listing | BSE, NSE |
| DRHP Draft Prospectus |  |
| RHP Draft Prospectus | |
Corona Remedies IPO Market Lot
The Corona Remedies IPO minimum market lot is 14 shares with ₹14,868 application amount. The retail investors can apply up-to 13 lots with 182 shares of ₹1,93,284 amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | 14 | ₹14,868 |
| Retail Maximum | 13 | 182 | ₹1,93,284 |
| S-HNI Minimum | 14 | 196 | ₹2,08,152 |
| S-HNI Maximum | 67 | 938 | ₹9,96,156 |
| B-HNI Minimum | 68 | 952 | ₹10,11,024 |
IPO Reservation
| Investor Category | Share Offered | -% Shares |
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | – Shares | 50% |
| NII Shares Offered | – Shares | 15% |
| Retail Shares Offered | – Shares | 35% |
Corona Remedies IPO Anchor Investors
| Anchor Bidding Date | December 5, 2025 |
| Anchor Investors List | |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| lock-in period end date 50% shares (30 Days) | January 10, 2026 |
| lock-in period end date 50% shares (90 Days) | March 11, 2026 |
Corona Remedies IPO Dates
The Corona Remedies IPO date is December 8 and the close date is December 10. The Corona Remedies IPO allotment will be finalized on December 11 and the IPO listing on December 15.
| IPO Open Date: | December 8, 2025 |
| IPO Close Date: | December 10, 2025 |
| Basis of Allotment: | December 11, 2025 |
| Refunds: | December 12, 2025 |
| Credit to Demat Account: | December 12, 2025 |
| IPO Listing Date: | December 15, 2025 |
| IPO Bidding Cut-off Time: | December 10, 2025 – 5 PM |
Promoters and Holding Pattern
The promoters of the company are Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta and Ankur Kirtikumar Mehta.
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 6,11,60,088 | 72.50% |
| Promoter Holding Post Issue | 6,11,60,088 | -% |
Corona Remedies IPO Company Financial Report
Amount ₹ in Crores
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ₹891.10 | ₹756.07 | ₹84.93 | ₹595.02 |
| 2024 | ₹1,020.93 | ₹859.74 | ₹90.50 | ₹830.58 |
| 2025 | ₹1,202.35 | ₹956.44 | ₹149.43 | ₹929.86 |
| June 2025 | ₹348.56 | ₹276.76 | ₹46.20 | ₹1,012.38 |
Corona Remedies IPO Valuation – FY2025
Check Corona Remedies IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 27.50% |
| ROCE: | 41.32% |
| EBITDA Margin: | 20.55% |
| PAT Margin: | 12.49% |
| Debt to equity ratio: | – |
| Earning Per Share (EPS): | ₹24.43 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 24.65% |
| Net Asset Value (NAV): | ₹99.14 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Abbott India Limited | 665.62 | 54.28 | 33.41% | 1,992.14 | 6,409.15 Cr. |
| Alkem Laboratories Limited | 181.11 | 32.96 | 18.07% | 1,002.37 | 12,964.52 Cr. |
| Eris Lifesciences Limited | 25.85 | 47.99 | 12.21% | 209.73 | 2,893.64 Cr. |
| GlaxoSmithKline Pharmaceuticals Limited | 54.76 | 83.53 | 47.54% | 115.19 | 3,749.21 Cr. |
| J.B. Chemicals & Pharmaceuticals Limited | 42.45 | 47.21 | 19.21% | 220.88 | 3,917.99 Cr. |
| Mankind Pharma Limited | 49.28 | 54.17 | 13.89% | 352.51 | 12,207.44 Cr. |
| Pfizer Limited | 167.79 | 34.56 | 18.20% | 921.88 | 2,281.35 Cr. |
| Sanofi India Limited | 179.46 | 23.76 | 48.05% | 373.68 | 2,013.20 Cr. |
| Torrent Pharmaceuticals Limited | 56.47 | 66.51 | 25.18% | 224.28 | 11,516.09 Cr. |
About the Corona Remedies IPO
Corona Remedies Limited, founded in August 2004, is one of the largest pharmaceutical companies that manufactures and sells products for women's health, heart care, pain relief, urology, and other treatments. Reportedly, Corona Remedies is the second-largest company in the Indian Pharmaceutical Market (“IPM”), out of 30 other companies. Furthermore, the company has a total of 88 R&D employees as of December 31, 2024.
The company offers 67 brands across various therapeutic areas, including women's healthcare, cardio-diabetes, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory). The company has a pan-India presence with 2,598 medical representatives in 22 states. It has two manufacturing facilities in the state of Gujarat.
Corona Remedies Limited, incorporated in August 2004, is a pharmaceutical company that develops, manufactures, and markets products in women's healthcare, cardiology, pain management, urology, and other therapeutic areas.
As of June 30, 2025, the company's diverse portfolio includes 71 brands across therapeutic areas such as women's healthcare, cardio-diabetes, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).
The company has a pan-India marketing and distribution network with 2,671 medical representatives across 22 states. This enables it to effectively connect with healthcare professionals and hospitals, strengthen its presence in IPM, and establish deep penetration in therapeutic areas.
The company has two manufacturing facilities located in Gujarat with a total installed capacity of 1,285.44 million units of formulations per year. Competitive Strengths:
The second-fastest growing company among the top 30 Indian pharmaceutical companies by domestic sales from MAT June 2022 to MAT June 2025, well-positioned to capitalize on opportunities in the Indian market.
Demonstrated ability to build a differentiated portfolio, including the "Engine" brand, in our targeted therapy areas.
Pan-India sales network and marketing strategy focus on the "middle of the pyramid" target market.
Manufacturing facility focused on quality and current good manufacturing practices, operates a diverse portfolio of pharmaceutical products with strong research and development capabilities.
Competent, experienced, and entrepreneurial management team supported by major investors.